Entrada Therapeutics Stock Today
| TRDA Stock | USD 19.83 0.46 2.37% |
Performance11 of 100
| Odds Of DistressLess than 23
|
Entrada Therapeutics is trading at 19.83 as of the 29th of November 2024, a 2.37 percent increase since the beginning of the trading day. The stock's open price was 19.37. Entrada Therapeutics has about a 23 % chance of experiencing some form of financial distress in the next two years of operation and had a somewhat good performance during the last 90 days. Equity ratings for Entrada Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of May 2023 and ending today, the 29th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 29th of October 2021 | Category Healthcare | Classification Health Care |
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle therapeutics for the treatment of multiple neuromuscular diseases. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts. The company has 37.42 M outstanding shares of which 1.61 M shares are at this time shorted by private and institutional investors with about 12.73 trading days to cover. More on Entrada Therapeutics
Moving together with Entrada Stock
| 0.7 | VTRS | Viatris | PairCorr |
| 0.84 | ESPR | Esperion Therapeutics | PairCorr |
| 0.73 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.85 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
Moving against Entrada Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Entrada Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO Director | Dipal Doshi | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsEntrada Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Entrada Therapeutics' financial leverage. It provides some insight into what part of Entrada Therapeutics' total assets is financed by creditors.
| |||||
Entrada Therapeutics (TRDA) is traded on NASDAQ Exchange in USA. It is located in One Design Center Place, Boston, MA, United States, 02210 and employs 177 people. Entrada Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 742.04 M. Entrada Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 37.42 M outstanding shares of which 1.61 M shares are at this time shorted by private and institutional investors with about 12.73 trading days to cover.
Entrada Therapeutics currently holds about 244.25 M in cash with 139.8 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.81.
Check Entrada Therapeutics Probability Of Bankruptcy
Ownership AllocationEntrada Therapeutics holds a total of 37.42 Million outstanding shares. The majority of Entrada Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Entrada Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Entrada Therapeutics. Please pay attention to any change in the institutional holdings of Entrada Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Entrada Ownership Details
Entrada Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-09-30 | 576.5 K | |
| State Street Corp | 2024-06-30 | 445.2 K | |
| Northern Trust Corp | 2024-09-30 | 247.7 K | |
| Jacobs Levy Equity Management, Inc. | 2024-09-30 | 201.8 K | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 186 K | |
| Millennium Management Llc | 2024-06-30 | 147.3 K | |
| Bank Of New York Mellon Corp | 2024-06-30 | 125.4 K | |
| Nuveen Asset Management, Llc | 2024-06-30 | 122.9 K | |
| Moore Capital Management, Lp | 2024-06-30 | 105 K | |
| Baker Bros Advisors Lp | 2024-09-30 | 4.9 M | |
| Mpm Asset Management, Llc | 2024-09-30 | 4.4 M |
Entrada Therapeutics Historical Income Statement
Entrada Stock Against Markets
Entrada Therapeutics Corporate Management
| Kory CPA | CFO Treasurer | Profile | |
| Kerry MS | Senior People | Profile | |
| Jared JD | General Counsel | Profile | |
| Nathan Dowden | Chief Officer | Profile | |
| Karla MacDonald | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Entrada Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entrada Therapeutics. If investors know Entrada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entrada Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.44 | Revenue Per Share 6.074 | Quarterly Revenue Growth (0.55) | Return On Assets 0.0695 | Return On Equity 0.1642 |
The market value of Entrada Therapeutics is measured differently than its book value, which is the value of Entrada that is recorded on the company's balance sheet. Investors also form their own opinion of Entrada Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Entrada Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entrada Therapeutics' market value can be influenced by many factors that don't directly affect Entrada Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entrada Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Entrada Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entrada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.